Assessment of the Effects of Tegaserod in the Management of Gastroesophageal Reflux Disease (GERD) in Patients With Incomplete Response to Proton Pump Inhibitors (PPIs).

PHASE3CompletedINTERVENTIONAL
Enrollment

54

Participants

Timeline

Start Date

June 30, 2003

Study Completion Date

February 28, 2005

Conditions
Gastroesophageal Reflux Disease (GERD)
Interventions
DRUG

Tegaserod

Trial Locations (2)

70001

Drug Research Services, Inc, Metairie

73104

The Oklahoma Foundation for Digestive Research, Oklahoma City

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Novartis

INDUSTRY

NCT00171418 - Assessment of the Effects of Tegaserod in the Management of Gastroesophageal Reflux Disease (GERD) in Patients With Incomplete Response to Proton Pump Inhibitors (PPIs). | Biotech Hunter | Biotech Hunter